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Moral Evils v. Health and Safety Evils: The case of an ovum µobtained¶ from a µdonor¶ and 
used by the µdonor¶ in her own surrogate pregnancy 
 
Pamela M. White 
   
INTRODUCTION 
2QHRIWKHPDQ\FULWLFLVPVOHYHOOHGDW&DQDGD¶VAssisted Human Reproduction Act, 2004 has 
been its lack of regulatory certainty.  By early 2018, only one set of regulations ± Section 8 
(Consent) Regulations ± had been passed.1  Ethicists,2 lawyers,3 and clinicians4 have repeatedly 
called on the federal government to take OHJLVODWLYHDFWLRQWRXSGDWH&DQDGD¶Vhuman sperm 
screening and testing regulation,5 address the lack of health protections for patients using 
donated ova,6 and to bring clarity to the law regarding reimbursement of gamete donors and 
surrogates.7  
 
The tide now appears to be finally turning. On October 1, 2016, Health Canada announced its 
intentions to bring forward a number of long awaited Assisted Human Reproductive Act 2004 
(AHRA)8 regulations. It plans to revise the 1996 Semen Regulations9 and move them from the 
                                                 
1
 SOR/2007-137 Assisted Human Reproduction (Section 8 Consent) Regulations. 
2
 )UDQoRLVH%D\OLV-RFHO\QH'RZQLHDQG'DYLG6QRZ³Fake it Till You Make it: Policy Making and Assisted 
+XPDQ5HSURGXFWLRQLQ&DQDGD´Journal of Obstetricians and Gynecologists Canada, 36(6):510±512; Jocelyne 
Downie and Francoise Baylis. ³7UDQVQDWLRQDOWUDGHLQKXPDQHJJVODZSROLF\DQGLQDFWLRQLQ&anada. Journal of 
Law and Medical Ethics 2013;41 (1):224±39. $ODQD&DWWDSDQ³5KHWRULFDQGUHDOLW\3URWHFWLQJZRPHQLQ&DQDGLDQ
SXEOLFSROLF\RQDVVLVWHGKXPDQUHSURGXFWLRQ´Canadian Journal of Women and the Law, 2013 25(2) 202. 
3
 Erin Nelson. Law, Policy and Reproductive Autonomy. 2013. Oxford. Hart Publishing at Chapter 9 and 326-334. 
4
 &%&1HZV³7HVWLPSRUWHGKXPDQHJJVGRFWRUVXUJH2YDVKRXOGPHHWVDPHVDIHW\VWDQGDUGVDVKXPDQVSHUP´
April 27, 2012; Arthur Leader, CBC Interview, 01.09.2016, http://www.cbc.ca/ottawamorning/episodes/#)  
5
 6WX0DUYHO³³7RQ\'DQ]D. 2013. ³,V0\6SHUP'RQRU"´4XHHU.LQVKLSDQGWKH,PSDFWRI&DQDGLDQ
5HJXODWLRQVDQG6SHUP'RQDWLRQ´Canadian Journal of Women and the Law, 25(2) 221. 
6
 9DQHVVD*UXEHQ³:RPHQDV3DWLHQWV1RWDV6SDUH3DUWV([DPLQLQJWKH5HODWLRQVKLS%HWZHHQWKH
3K\VLFLDQDQG:RPHQ(JJ3URYLGHUV´Canadian Journal of Women and the Law, 25(2) 249.  
7
 $OLVRQ0RWOXN³7KHKXPDQHJJWUDGH+RZ&DQDGD¶VIHUWLOLW\ODZVDUHIRROLQJGRQRUVGRFWRUVDQGSDUHQWV´The 
Walrus, 2010: 1-8; R v Leia Picard and Canadian Fertility Consulting Ltd 2013.  
8
 Assisted Human Reproduction Act 2004 c2. 
9
 SOR/96-254 Processing and Distribution of Semen for Assisted Conception Regulations. 
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Food and Drugs Act to the AHRA (amended 2012), develop regulations for the screening and 
testing of ova donors, establish gamete tracing protocols, clarify reimbursable expenses for 
parties involved in surrogacy arrangements and sperm and ova donation, and institute inspection 
procedures.10  Health Canada cites three reasons for undertaking this long overdue legislative 
renewal: i) reduce the risks to human health and safety from using donor sperm and eggs (ova), 
including the risk of transmitting disease; ii) make clear what expenses may be reimbursed to 
donors and surrogates; and, iii) allow the appointment of inspectors who will manage and 
enforce the AHRA.11   
 
Since the October 2016 announcement, Health Canada has undertaken web-based consultations 
and invited stakeholders and interested parties to comment on its proposed directions for 
regulatory change. Consultation has occurred alongside the 6WDQGDUGV&RXQFLORI&DQDGD¶VUH-
development and re-release in late 2017 of a revised National Standard of Canada, CAN/CSA-
Z900.2.1.-17 Tissues for assisted reproduction.12 This updated Standard is a propriety set of 
guidelines though it should be noted that its development like the earlier versions was funded by 
Health Canada.13 It is expected that the 2017 CAN/CSA Standard will shape the detailed 
screening, testing, labelling and packaging and reimbursement regulations likely to be tabled in 
                                                 
10
 Health Canada. Press release: Government of Canada plans to introduce regulations to support the Assisted 
Human Reproduction Act. http://news.gc.ca/web/article-en.do?nid=1131339&tp=1. Canada Gazette Vol. 150, No. 
40 ² October 1, 2016. Government Notices, Department of Health, Assisted Human Reproduction Act.  
11Health Canada, Strengthening the Assisted Human Reproduction Act. October 1, 2016. 
https://www.canada.ca/en/health-canada/programs/consultation-assisted-human-reproduction.html 
12
 Standards Council of Canada. CAN/CSA-Z900-17 Tissues for assisted reproduction. December 2017. See page 8 
for a list of clinicians, embryologists and the patient group (LGBTQ Parenting Network) involved in the 
development of the 2017 CAN/CSA Standard. 
13
 In January 2018, the cost for the standard was $165.00 plus HST.  This cost provides the purchaser with an 
independent licence to access the Standard. The purchaser is also entitled to obtain updates. 
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the 2018-19 Parliamentary Session or possibly incorporated into the regulations.14 
In early February 2018, Health Canada released a VKRUWRYHUYLHZUHSRUWHQWLWOHG³What We 
Heard´.15 It summarized WKH³VHWVRIFRPPHQWV´16 received during the 2016-17 consultation 
period but did not reveal the direction that the government was likely to take in response to 
identified concerns. Nor did it suggest how conflicting views might be addressed.  
 
While these initiatives indicate that the federal government has at long last decided to take action 
to resolve some of the longstanding AHRA regulatory inadequacies, the approach falls short of a 
much-needed legislative renewal being requested by those seeking changes to the sections that 
ban commercial surrogacy and gamete donation17 and limit research.18  Also, there has been very 
little attention paid to the legal and policy implications of the amendments made in 2012 to the 
AHRA.19  
 
This paper critically examines one of the 2012 AHRA amendments. At section 10 of the Act, a 
new requirement was added mandating screening and testing of µobtained¶ ovum µdonated¶ by a 
µGRQRU¶and used in her own surrogate pregnancy.20 The stated rationale for this amendment cites 
                                                 
14It should be noted that the 2017 CAN/CSA Standard also includes an itemization of the legitimate expenses for 
which gamete donors and surrogates should receive reimbursement. 6HH0DUN&0F&OHRG³&KDSWHU
Reimbursement of Expenditures and Possible Sub-delegation of the Assisted Human 5HSURGXFWLRQ5HJXODWLRQV´LQ
V. Gruben, A. Cameron and A. Cattapan, V. Gruben, A. Campbell & A. Cattapan (eds) Surrogacy in Canada: 
Critical Perspectives in Law and Policy. Toronto: Irwin Law. Forthcoming 2018. 
15




 Health Canada, 2018.Ibid., at 1. 
17
 Canadian Fertility and Andrology Society. CFAS Position Statement: Compensation for Third Party Reproduction 
in Canada. May 11, 2017.  Available at: https://cfas.ca/guidelines/position-statements/. 
18
 Alison Motluk, 2018. ³Fertility advocates protest criminal sanctions in assisted reproduction act´Canadian Medical 
Association Journal, January 15, 2018 190 (2) E58-E59; DOI: https://doi.org/10.1503/cmaj.109-5544 
19
 $ODQD&DWWDSDQDQG6DUD&RKHQ³7KH'HYLO:H.QRZ7KH,PSOLFDWLRQVRI%LOO&-38 for Assisted Human 
5HSURGXFWLRQLQ&DQDGD´. Journal of Obstetrics and Gynaecology Canada 35(7): 654. 
20
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19, at s.714 
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the IHGHUDOJRYHUQPHQW¶VREOLJDWLRQto reduce harm to human health and safety arising from use 
of sperm or ova for human reproduction, including the risk of the transmission of disease.21 The 
2016 Health Canada regulatory initiative advanced to establish the mandated screening and 
testing regime instituted to ensure the health of Canadian fertility patients will be required to 
address this recently added legislative requirement.  
 
The paper identifies three issues raised by the amendment targeting traditional surrogacy22 when 
carried out as a result of assisted reproduction technologies.23 The first observes that failure to 
VFUHHQDQGWHVWDZRPDQ¶VREWDLQHGRYum used in her own surrogate pregnancy carries criminal 
code penalties. The Supreme Court of Canada (SCC) decision in Reference re Assisted Human 
Reproduction Act (Ref re AHR)24 permits the federal government to legislate in areas where a 
µKHDOWKHYLO¶LVSUHVHQWThe paper LQYHVWLJDWHVWKHµKHDOWKevil¶ that requires the application of 
federal criminal law powers to mandate screening and testing of an µobtained¶ ovum µGRQDWHG¶ 
by a woman and used in her own surrogate pregnancy?25 It asks: Are we satisfied that the 
amendment meets the harm test for application of criminal law powers established by the SCC in 
Ref re AHR.26 
   
The second issue FRQFHUQVWKHWHUPµGRQRU¶7KHSDSHUDUJues that a muddling of the meaning of 
                                                 
21
 S.10(1) as amended by Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19, at s.714.  
22
 Traditional surrogates are genetically related to the child they agree to carry for intended parent(s).  They supply 
their own ova used in their surrogate pregnancy.  
23
 Most traditional surrogacy occurs as a result of assisted insemination. The amendment is directed at IVF 
WUHDWPHQWVZKHUHE\WKHVXUURJDWH¶VRYXPRYDDUHREWDLQHGDVDUHVXOWRIRYDULDQVWLPXODWLRQ7KHex utero ovum 
would then be fertilized using sperm from the intended parent or by sperm obtained for the reproductive use of the 
intended parent(s).  
24
 8EDND2JEXJX³7KH$VVLVWHG+XPDQ5HSURGXFWLRQ$FW5HIHUHQFHDQGWKH7KLQ/LQH%HWZHHQ+HDOWKDQG
&ULPH´Constitutional Forum constitutionnel 22(1), 93-97. 
25
 Assisted Human Reproduction Act S.C.2004, c2. s 10(2)(c) amended 2012. 
26
 Reference re Assisted Human Reproduction Act, 2010 SCC 61, [2010] 3 S.C.R. 457.  
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the word µGRQRU¶appears to have been introduced by the amendment.  I suggest that 
terminological confusion created by the AHRA, use of a different definition by the 2017 
Canadian Standards Association Standard, provincial statutes, and Canadian Fertility and 
Andrology Society treatment guidance documents may be contributing to a misunderstanding 
regarding the health and safety risks encountered by a woman using her own µobtained¶ ova in 
her own surrogate pregnancy. I critically explore the implications of this confusion for 
reproductive law and policy.  
 
The third issue raised by the amendment centres on the transformation of an µown ovD¶ into a 
µWhird-party¶ gamete. ThLVRFFXUVLQSDUWE\WKHFRQIXVLRQRYHUWKHZRUGµGRQRU¶EXWLWLVa more 
complex matter. I argue that the multi-faceted fertility treatment roles taken on by the traditional 
surrogate can result in her being both an µHJJGRQRU¶DQGa µVXUURJDWH¶7KHSDSHr asks us to 
focus our attention on elements of consent that could become especially problematic for 
traditional surrogates, including consent for testing and screening, consent to donate, consent for 
treatment as a donor and as a traditional surrogate, and consent to create an embryo. This 
multiplicity of roles demands that assisted reproduction legislation and accompanying 
regulations need to regard her as an autonomous, consenting fertility patient DQGQRWDVD³VSDUH
SDUW´27 SURYLGHURUDVD³WUHDWPHQWRSWLRQ´ for infertile patients and intended parent(s).28   
 
                                                 
27
 Vanessa Gruben. 2009. ³Assisted Reproduction Without Assisting Over-Collection: Fair Information Practices 
DQGWKH$VVLVWHG+XPDQ5HSURGXFWLRQ$JHQF\RI&DQDGD´Health Law Journal 17: 229. 
28
 3DPHOD0:KLWH³:K\ZHGRQ¶WNQRZZKDWZHGRQ¶WNQRZ¶DERXW&DQDGD¶VVXUURJDF\SUDFWLFHVDQGRXWFRPHV´
in A. Cattapan, A. Campbell and V. Gruben (eds). &ULWLFDO$SSURDFKHVWR&DQDGD¶V6XUURJDF\/DZIrwin Law. 
2018 (forthcoming).   
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To undertake the analysis of the three substantive issues, the first section of the paper conducts a 
a review of &DQDGD¶VDVVLVWHGUHSURGXFWLRQOHJDOODQGVFDSH,WWKHQexamines the AHRA 
definitiRQRIµGRQRU¶ and considers how the AHRA concept differs from the terminology used in 
in provincial statutes, the 2017 CAN/CSA Standard, and fertility association guidelines. The 
paper then chronicles the amendments made to the AHRA in 2012 that require screening and 
testing of human reproductive tissue used in fertility treatments. In this section, I explore a 
number of implications of the amendment for issues such as consent, reproductive autonomy, 
and health risks.  
 
Once establishing the parameters and factors included in the legislative AHR Act amendment, 
the second section of the paper undertakes an analysis of health and safety harms that could be 
be viewed as conditions sufficient to require the imposition of criminal law sanctions were 
untested and unscreened µobtained¶ traditional surrogate ova used in the tUDGLWLRQDOVXUURJDWH¶V
pregnancy. I seek to establish whether the health and safety harms would be to the traditional 
surrogate herself, the clinic, other fertility patients, surrogate-born child, or to society in general. 
It asks whether the identified health and safety harms meet the test set out by the SCC in Ref re 
AHR.  
 
The final section of the paper critically analyses a number of problems identified with the 
amendment, including whether there exists a sufficient health and safety justification to impose 
criminal code penalties in cases where unscreened and untested µobtained¶ ova µdonated¶ by a 
traditional surrogate are used in her own surrogate pregnancy. It probes whether the proposed 
regulatory actions it triggers function as a thinly disguised attempt to discourage the practice of 
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traditional surrogacy when undertaken using IVF. It asks whether the screening and testing 
requirement could be an attempt to turn traditional surrogates into a special group of designated 
ova donors: women who also take on an additional role as surrogate. In conclusion, it focusses 
our attention on several of the worrisome regulatory problems that are likely to be created as a 
rHVXOWRILQFRQVLVWHQWDSSOLFDWLRQRIWKHWHUPµGRQRU¶UHOLDQFHRQXQHOHFWHGbodies to determine 
regulatory framework parameters,29 and an uncritical sanctioning of fertility industry practices.  
 
BRIEF HISTORY OF ASSISTED HUMAN REPRODUCTION ACT, 2004 
CanadD¶VAHRA 2004 passed after nearly 20 years of extensive consultation,30 in-depth study31 
and at times acrimonious debate32 is considered by many legal and policy scholars to be 
seriously flawed.33 Barely had the Act achieved Royal Assent when Quebec contested the use of 
federal criminal law powers to regulate the practice of fertility medicine.34 In 2010, the SCC 
DJUHHGZLWK4XHEHF¶VSRVLWLRQLQLWVFRQWHVWHGDQGGLYLGHGGHFLVLRQ:1) Ref re AHR which 
rendered ultra vires the sections of the Act legislating in areas under provincial constitutional 
                                                 
29
 Frank Vibert. 2007. The Rise of the Unelected: Democracy and the New Separation of Powers. Cambridge: 
Cambridge University Press. 
30
 Royal Commission on New Reproductive Technologies "Proceed with Care´2WWDZD4XHHQ¶V3ULQWHU
known as the Baird Commission; Bonnie Brown, December 2001. Assisted Human Reproduction: Building 
Families. Standing Committee on Health. December 2001.Parliamentary Internet Parlementaire: 
http://www.parl.gc.ca. 
31
 Ibid. note %DLUG&RPPLVVLRQUHVHDUFKUHSRUW³Proceed with Care´ZDVYROXPLQRXV/LVWRIUHVHDUFKVWXGLHV
and researchers, Appendix E at 1253-71.  
32
 Monique. Hébert, Nancy M. Chenier and Sonia Norris. 10 October 2002 (revised 16 April 2003) Legislative 
History of Bill C-13. Library of Parliament.   
33
 Pamela M. White, 2015. ³$µOHVVWKDQSHUIHFWODZ¶7KHXQIXOILOOHGSURPLVHRI&DQDGD¶V$VVLVWHG+XPDQ  
5HSURGXFWLRQ$FW´LQ.LUVW\+RUVH\(ed.), Human Fertilisation and Embryology: Regulation Revisited (London: 
5RXWOHGJH)UDQoRLV%D\OLVDQG-RFHO\QH'RZQLH³$7DOHRI$VVLVWHG+XPDQ5HSURGXFWLRQ&DQDGD$
7UDJHG\LQ)LYH$FWV´Canadian Journal of Women and the Law, $ODQD&DWWDSDQ³5KHWRULFDQG
UHDOLW\3URWHFWLQJZRPHQLQ&DQDGLDQSXEOLFSROLF\RQDVVLVWHGKXPDQUHSURGXFWLRQ´Canadian Journal of Women 
and the Law, 25(2) 202.  
34Décret 1177-2004; Décret 73-2006; Attorney General of Quebec v Attorney General of Canada, 2008 QCCA 
1167, [2008]. RJQ 1551, 298 DLR (4th) 712. 
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jurisdiction, notably the practice of medicine and research.35 The SCC decision left intact the 
sections protecting human health and safety, such as the testing and screening of human 
reproductive materials used for assisted reproduction.36  The prohibition of activities deemed to 
be morally unacceptable such as cloning, sex selection, discrimination and commodification of 
human gamete donation and surrogacy were upheld37 as were the sections enabling enforcement 
of permitted activities, including the reimbursement of expenses incurred by gamete donors and 
surrogates.38 
 
The pith and substance39 of the SCC 2010 decision, Ref re AHR, centres on the use of federal 
criminal law powers to uphold morality and to prohibit a public health evil.40 Relying on the 
argumentation advanced by Rand J in the Margarine reference,41 Ref re AHR reaffirms that the 
evil or threat must be real and legitimate.42 Moreover, the decision serves to remind Canadian 
legislators that in matters of health, an area of provincial constitutional responsibility, criminal 
law when used to achieve a public purpose is restricted to suppression of a public health evil.43 It 
underscores that mere identification of public purpose is not sufficient justification for invoking 
                                                 
35
 2010 SCC 61 [2010] 3 S.C.R. 457. Sections rendered ultra vires: s. 10, 11, 13-18; ss 40(2) (3), (3.1), (4) and (5) 
and ss. 44(2) and (3). 
36
 See the new section 10, Assisted Human Reproductive Act, 2004 as amended in 2012.  
37
 Supra note 8, sections 5-9.   
38Discussion of the decision found at:  B. Von Tigerstrom. 2011.³)HGHUDOKHDOWKOHJLVODWLRQDQGWKHAssisted Human 
Reproduction Act Reference´Saskatchewan Law Review, 74:33; JD. Whyte. 2011. ³)HGHUDOLVPDQGPRUDO
regulation: A comment on the Reference re Assisted Human Reproduction Act´Saskatchewan Law Review, 74: 45. 
GG Mitchell. 2011. ³1RWDJHQHUDOUHJXODWRU\SRZHU- A comment on Reference re Assisted Human Reproduction 
Act´Supreme Court Law Review, 54:633. See section 12 of the AHRA. 
39
 The purpose and effect see: 2010 SCC 61 [2010] 3 S.C.R. 457 at 189.  
40
 J-F Gaudreault-DesBiens & N. Karazavin³&DQDGD¶V1HZ5HSURGXFWLYH7HFKQRORJLHV$0RUDO(YLORU
6LJQVRI%HQHILFLDO0HGLFDO3URJUHVV"´Public Law (January) 147; JD. Whyte. 2011. ³)HGHUDOLVPDQGPRUDO
regulation: A comment on the Reference re Assisted Human Reproduction Act´Saskatchewan Law Review, 74: 45 
41
  Reference re Validity of Section 5 (a) of the Dairy Industry Act, [1949] SCR 1, 1 DLR 433. 
42
 2010 SCC 61 [2010] 3 S.C.R. 457 at para 251. 
43
 Ubaka Ogbogu, 2013. ³The Assisted Human Reproduction Act Reference and the Thin Line Between Health and 
&ULPH´  Constitutional Forum constitutionnel 22(1): 93 at 93. 
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federal criminal law powers. As the SCC stated that the ³HYLOPXVWEHUHDO and the apprehension 
RIKDUPPXVWEHUHDVRQDEOH´44  I argue that it is through this interpretive lens that subsequent 
AHRA legislative amendments and regulatory reform such as the one recently undertaken by 
Health Canada must be critically assessed and evaluated.   
 
2012 Legislative Amendments to the AHRA 
In March 2012, more than two years after the decision in Ref re AHR, the federal government 
used omnibus tax legislation, Bill C-38: Jobs, Growth and Long-term Prosperity, to amend the 
Assisted Human Reproductive Act, 2004.45  The Assisted Human Reproduction Agency was 
eliminated thereby saving the federal government some $10 million46 though it soon become 
apparent that any fiscal savings were likely to be considerably less given that the Agency had 
never managed to spend even half of its annual budget.47 Furthermore, Health Canada was being 
asked to assume a limited number of assisted reproduction regulatory, enforcement, and outreach 
responsibilities.48   
 
The 2012 Jobs, Growth and Long-term Prosperity Act amendments also performed a legal 
administrative housekeeping function consistent with a regulatory stance current at the time that 
                                                 
44
 2010 SCC 61 [2010] 3 S.C.R. 457 at 464.  
45




,QGXVWU\´National Post. 30 March 2012;  
47
 $QQH.LQJVWRQ³$VVLVWHG+XPDQ5HSURGXFWLRQ&DQDGD7KH%XGJHW&XW(YHU\RQH0LVVHG´0DFOHDQ¶V&DQDGD, 




RI$VVLVWHG+XPDQ5HSURGXFWLRQ&DQDGD$7UDJHG\LQ)LYH$FWV´Canadian Journal of Women and the Law, 
25(2) 183.  
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of eliminating one regulation for every new one it established.49 The sections of the Act rendered 
ultra vires by the SCC decision in Ref re AHR were repealed. At the same time, it consolidated a 
number of regulatory responsibilities found in or identified as being absent from accompanying 
legislation. For example, sections of the AHRA 2004 that regulated the use of human ova and 
sperm under the Human Pathogens and Toxic Materials Act50 along with the regulation that had 
mandated the testing and screening regime for human sperm under the federal Food and Drugs 
Act51 were repealed. Human sperm and ova screening and testing along with tracing and 
identification requirements are now found within the ambit of the AHRA at the amended s.10. 
The investigative abilities of Health Canada were strengthened.  Inspection provisions associated 
with the as-yet-to-be promulgated regulations were revised52.  
 
The 2012 AHRA amendments have been characterised by some scholars as a repeat performance 
of a failed legislative project,53 while others have been less generous in their criticism of 
&DQDGD¶Vrenewed legislative foray into the law of assisted reproduction.54  However, none of the 
critiques of the 2012 AHR Act amendments have examined the implications of imposing 
screening and testing regulations on µobtained¶ ova µdonated¶ by a traditional surrogate for use in 
                                                 
49
 Laura Jones, 2015. ³Cutting Red Tape in Canada: A Regulatory Reform Model for the United States?´ Mercatus 
Research, Mercatus Center at George Mason University, Arlington, VA, November:3. 
50
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19, at s.714. 
51
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19 at s.715. 
52
 AHRA 2004 s.45-68. 
53
 Alana Cattapan & Sara Cohen. ³7KH'HYLO:H.QRZ7KH,PSOLFDWLRQVRI%LOO&-38 for Assisted Human 
Reproduction in &DQDGD´Journal of Obstetrics and Gynaecology Canada 35(7): 654.  
54
 François Baylis & -RFHO\QH'RZQLH³$7DOHRI$VVLVWHG+XPDQ5HSURGXFWLRQ&DQDGD$7UDJHG\LQ)LYH
$FWV´Canadian Journal of Women and the Law, 25(2):183 
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her own surrogate pregnancy55; a requirement added to the Act without public consultation or 
discussion by Parliament.56  
 
In the absence of careful scrutiny, we need to look closely at the implications for reproductive 
law and policy of a legislative change involving traditional surrogates.  If the objective is to 
discourage the practice, then the requirement to screen and test obtained own ova used by a 
traditional surrogate delivers an unexpected punitive punch.  On the other hand, if the purpose is 
to protect the traditional surrogate and her offspring from a health harm, the identified health 
risks need to be real and the protective measures proportionate. Finally, if the goal is to shelter 
Canadians from the harm of a moral evil, one needs to be able to determine why traditional 
surrogacy when performed through IVF as that is the only way to µobtain¶ ova from a woman 
constitutes an evil that is absent when traditional surrogacy occurs as a result of artificial 
insemination, which is the more common practice.   
 
2012 AHRA Section 10 amendments 
The 2012 AHRA amendments at section 10 replace the original s.1057 rendered ultra vires by the 
SCC in Ref re AHR.  The purpose of the impugned s.10 had been to support a federally 
controlled and managed licencing regime for human gametes used in assisted human 
                                                 
55
 Glenn Rivard³)HGHUDODQG3URYLQFLDO-XULVGLFWLRQVZLWK5HVSHFWWR+HDOWK6WUXJJOHVDQG6\PELRVLV´LQ7
Lemmens, A. F. Marin, C. Milne & I.B. Lee (eds) Regulating Creation: The Law, Ethics and policy of Assisted 
Reproduction. Toronto: University of Toronto Press. 63 at 80-82. Rivard makes no reference to the requirement to 
screen and test of surrogate ova donors.   
56
 Bill C-38 passed without discussion as to the amendments being made to the AHRA apart from Mr Wayne 
Marston (Hamilton East-Stony Mountain, NDP) noting that the Assisted Human Reproduction Agency would be 
shut down. Hansard, 1st Session, 41 Parliament. Monday, June 18, 2012, Vol.146, No. 142 (Part A) at 9693 and Ms 
Megan Leslie (Halifax, NDP) who asked about the fiscal savings to be achieved from the shutdown of the Assisted 
Human Reproduction Agency. Hansard. 1st Session, 41st Parliament, Friday June 15, 2012 at 9612. 
57
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19 at s.717. 
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reproduction.58  With this type of federal activity ruled constitutionally invalid, the federal 
government repositioned its legislative responsibilities and subsequent use of criminal code 
powers to fall within a human health protection mandate.  Indeed, at s.10(1) the health objective 
of testing and screening of human gametes used in assisted human reproduction is stated as 
being:  
10. (1) The purpose of this section is to reduce the risks to human health and safety 
arising from the use of sperm or ova for the purpose of assisted human reproduction, 
including the risk of the transmission of disease. 
 
In the subsections that follow on from s.10(1), human sperm and ova obtained from specified 
types of donors at s.10(2)(a, b, c) and used by certain categories of female persons at s.10(2)(a, b, 
c) for the purposes of  assisted reproduction may be exempted from testing and screening as 
indicted in s. s. 10(3)) and can be distributed and imported pursuant to s.10(4)). It should also be 
noted that at s.10(5) WKHWHUPµcommon-law partner¶ is defined and at s. 61, an amended set of 
penalties for failure to abide by the regulations to be promulgated pursuant to s.10 are specified. 
 
Finally, AHRA prohibits all uses of human gametes and embryos in assisted human reproduction 
unless the activity is expressly permitted by regulation.59 The amendments made in 2012 
preserve this position. As a result, assisted reproduction is characterised as a non-normative and 
unnatural activity. This characterization may have had salience in the 1980s when the practice 
was innovative but is less defensible today. Certainly, the acceptability of the practice was focus 
of debate in the SCC decision in Ref re AHA.  The AHRA, at s.10, explicitly legalises a fertility 
                                                 
58
 2010 SCC 61 [2010] 3 S.C.R. 457. Sections rendered ultra vires: s. 10, 11, 13-18; ss 40(2) (3), (3.1), (4) and (5) 
and ss. 44(2) and (3). 
59
 The Section 8 (Consent) Regulations are silent with respect to destruction of embryos no longer wanted for 
reproductive use, training or research. 
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paWLHQW¶Vuse of their own unscreened and untested ova and the unscreened and tested sperm and 
ova of their spouse, common-law partner or sexual partner. It makes the reproductive use of all 
other unscreened and untested human reproductive material illegal on the grounds of health and 
safety risks.  
 
Identification of the type of donated sperm and ovum to be tested and screened 
6HFWLRQDPHQGPHQWVLQWURGXFHGE\WKHJobs, Growth and Long-term Prosperity$FW
F'LYLVLRQVWDWH60 
 
10. (2) Subject to subsection (3), no person shall distribute, make use of or import any of the 
following for the purpose of assisted human reproduction: 
(a) sperm that has been obtained from a donor and that is meant for the use of a 
female person other than a spouse, common-law partner or sexual partner of the donor; 
(b) an ovum that has been obtained from a donor and that is meant for the use of a 
female person other than the donor or the spouse, common-law partner or sexual partner 
of the donor; or 
(c) an ovum that hDVEHHQREWDLQHGIURPDGRQRUDQGWKDWLVPHDQWIRUWKHGRQRU¶VXVHDV 
a surrogate mother. 
 
10(3) Subsection (2) does not apply if: 
(a) tests have been conducted in respect of the sperm or ovum in accordance with the 
regulations, and the sperm or ovum has been obtained, prepared, preserved, quarantined, 
identified, labelled and stored and its quality assessed in accordance with the regulations; 
and 
(bWKHGRQRURIWKHVSHUPRURYXPKDVEHHQVFUHHQHGDQGWHVWHGDQGWKHGRQRU¶V
suitability has been assessed, in accordance with the regulations. 
 
10 (4) No person shall, except in accordance with the regulations, engage in any activity 
described in paragraph (3)(a) or (b) in respect of any of the following with the intention of 
distributing or making use of it for the purpose of assisted human reproduction: 
(a) sperm described in paragraph (2)(a); 
(b) an ovum described in paragraph (2)(b); or 
(c) an ovum described in paragraph (2)(c). 
 
10 (5) In this section, ³common-law partner,´ in relation to an individual, means a person who is 
cohabiting with the individual in a conjugal relationship at the relevant time, having so cohabited 
                                                 
60
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19 at s.714-718.  
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for a period of at least one year.61 
 
The penalties for failure to screen, test, label, distribute and import as specified in the regulations 
are set out in s.61.62  
61. A person who contravenes any provision of this Act²other than any of sections 5 to 7 and 
9²or of the regulations or an order made under subsection 44(1) is guilty of an offence and 
(a) is liable, on conviction on indictment, to a fine not exceeding $250,000 or to imprisonment 






The above noted sub-sections 10(2) (a, b, and c) begin by identifying gametes ± sperm and ovum 
± obtained from three different types of µdonors¶. But before we examine who are the µdonors¶ 
and whether their gametes need to be tested and screened, we need to understand what the 
$+5$PHDQVE\WKHWHUPµGRQRU¶ 
 
In law, the AHRA situates the act of donation ± the giving, granting or conferring of human 
reproductive material ± to the person from whose body the ovum or sperm was obtained.  The 
Act considers all persons undertaking IVF treatment to be µdonors¶ even if the µdonation¶ is 
made to oneself in the form of autologous/own use or when sperm or ovum are to be used by the 
GRQRU¶Vspouse, common-law or sexual partner. 
The AHRA at s.3, defines µdonor¶ as:  
³(a) in relation to human reproductive material, the individual from whose body it was 
obtained, whether for consideration or not; and 
                                                 
61
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19 at s. 718.  
62
 Jobs, Growth and Long-term Prosperity Act, S.C. 2012, c-19 at s. 735. 
63
 No regulations pursuant to the amended s.10 have been made. Penalties for failure to test and screen human sperm 
are specified in the Processing and Distribution of Semen for Assisted Conception, SOR/96-254. May 7, 1996.  
   
 15 
(b) in relation to an in vitro embryo, a donor as defined in the regulations.´64 
 
The Section 8 (Consent) Regulations PDLQWDLQVWKHEURDGGHILQLWLRQRIWKHWHUPµGRQRU¶DQGWKH
µDFWRIGRQDWLRQ¶,WVSHFLILHs permitted uses, including own-use, third-party reproductive use, 
research and testing all of which PXVWEHXQGHUWDNHQZLWKWKHFRQVHQWRIWKHµGRQRU¶ or donors in 
the case of an embryo.65 Its goal is to ensure that all fertility patients are enabled to excise 
autonomy.66  However it should be noted that the Section 8 (Consent Regulations) clearly 
GHILQHVWKH³WKLUG-SDUW\¶WREHVHSDUDWHDQGDSDUWIURPWKHµGRQRU¶RIWKHRYDVSHUPRUHPEU\R
used in assisted reproduction.67  
 
2QHPDMRUGLIILFXOW\FUHDWHGE\WKH$+5$GHILQLWLRQRIµGRQRU¶applied to the person as µdonor¶ 
(noun) and the µact of JLYLQJ¶verb) ± donating is that it encompasses in law both concepts: a 
µdonor¶ who gives to oneself as well as DµGRQRU¶ZKRgives human reproductive material to 
others. In so doing, it confounds and blurs common-use definitions of µdonor¶ and µdonation¶.   
 
The Oxford Dictionary, for example, defines µGRQRU¶DVthe person who is involved in an act of 
giving.  This means that the act of donation is other-motivated and other-directed³a donor is a 
person who gives (donates) blood, organs or reproductive tissues to a third-party.´68  Yet, the 
                                                 
64
 Assisted Human Reproduction Act 2004 c2, s.3.  
65
 Assisted Human Reproduction (Section 8 Consent) Regulations. SOR/2007-137 state that donor must provide 
consent for creation and use of an embryo: (i) for their own reproductive use; (ii) use following death; (iii) third-
party use; and (iv) research (including IVF instruction).  No changes have been introduced to the Section 8 Consent 
Regulations as a result of the s.10 amendments.  
66
 Glenn Rivard and Jill Hunter. The Law of Assisted Human Reproduction. Toronto: Lexis Nexis Butterworths 
(2005) at 39-40. 
67 Assisted Human Reproduction (Section 8 Consent) Regulations. SOR/2007-137 at s. 1(a) (i) and 1(a (ii). 
68
 Oxford Dictionary. Origin from Latin donator, donare: to give.  
³$SHUVRQZKRGRQDWHVVRPHWKLQJHVSHFLDOO\PRQH\WRFKDULW\´ ³$SHUVRQZKRSURYLGHVEORRGDQRUJDQRU
VHPHQIRUWUDQVSODQWDWLRQWUDQVIXVLRQ´ 
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AHRA takes a much broader view of who is a donor and the act of giving as it considers the 
donor and the act of donation to include giving of a gamete or embryo to oneself as well as to 
RWKHUVLQFOXGLQJRQH¶VVSRXVHcommon-law or sexual partner in addition to anonymous or 
known third-parties for their reproductive uses or for research and training.  
 
To further complicate the matter, the $FW¶Vterminology differs from language adopted by 
provincial statutes,69 fertility association recommendations and guidelines,70 and the 2017 
CAN/CSA Standard.71 ,QWKHVHLQVWDQFHVWKHWHUPµGRQRU¶UHIHUVWRthe person who donates 
human reproductive material or embryos for the reproductive use by a third-party.  
 
When we look at how the term µGRQRU¶LVGHILQHGDQGXVHGLQSrovincial statutes and judgements, 
we see clearly just how different LVWKH$+5$GHILQLWLRQRIµGRQRU¶For example, in a British 
Columbia case involving traditional surrogacy, Family Law Act (Re) 2016 BCSC 598, Fitzpatrick 
J determined that the petitioner, ³.*GRHVQRWFRPHZLWKLQWKHGHILQLWLRQRID³GRQRU´VLQFHKLV
GRQDWLRQRIVSHUPIRUWKHFRQFHSWLRQZDVIRUKLV³RZQUHSURGXFWLYHXVH´72 This ruling is guided 
by the British Columbia Family Law Act definLWLRQRIDµdonor¶: 
³a person who, for the purposes of assisted reproduction other than for the person's own 
reproductive use, provides: 
(a) his or her own human reproductive material, from which a child is conceived; or 
       (b) an embryo created through the use of his or her human reproductive material.´73  
                                                 
69
 Family Law Act [SBC 2011] Chapter 25; Legislature of Ontario. Bill 28, All Families Are Equal Act (Parentage 
and Related Registrations Statute Law Amendment), 2016. 2QWDULRVLGHVWHSVWKHXVHRIWKHWHUPµGRQRU¶E\PDNLQJ
the action of donation of reproductive material a negative action as it concerns parentage. ³Provision of reproductive 
material, embryo not determinative. 5. (1) A person who provides reproductive material or an embryo for use in 
assisted reproduction: (a) is not, by reason only of the provision, a parent of the child; and (b) shall not, by reason 
RQO\RIWKHSURYLVLRQEHUHFRJQL]HGLQODZWREHDSDUHQWRIWKHFKLOG´ 
70
 Jon Havelock et al. 2016. Canadian Fertility and Andrology Society Guidelines for Third Party Reproduction. 
Montreal: Canadian Fertility and Andrology Society at 2: 
71
 Standards Council of Canada, Tissues for assisted reproduction´&$1&6$-Z900.2.1-17, December 2017 at 17. 
72
 Family Law Act (Re) 2016 BCSC 598 at 17. 
73
 Family Law Act [SBC 2011] Chapter 25, Part 3: Parentage, s.20. 




The Canadian Fertility and Andrology Society publication, Guidelines for Third Party 
Reproduction, adopts a similar definition to one used in the British Columbia Family Law Act.  A 
gamete donor is defined as being: ³a person who donates oocytes or sperm to a known or 
anonymous recipient for the purpose of achieving a pregnancy for the recipient and their partner 
(if applicable).´74 
 
The 2017 CAN/CSA Standards document considers a donor to be a provider of gametes or an 
embryo for third-party use.  This document, which is expected to shape federal testing and 
screening regulations, defines a µdonor¶ as ³DQLQGLYLGXDOZKRprovides reproductive tissues for 
use in a recipient who is not his or her spouse, common law partner, or sexual partner, in 
DFFRUGDQFHZLWKHVWDEOLVKHGPHGLFDOFULWHULDDQGSURFHGXUHV´75  The 2017 CAN/CSA Standard 
acknowledges that the AHRA provides a broader definition RIµdonor¶: ³LQUHODWLRQWRKXPDQ
reproductive material, the individual from whose body it was obtained, whether for consideration 
or not.´  However, the 2017 CAN/CSA Standard does not explicitly adopt the broader AHRA 
definition of donor with the result that the screening and testing procedures it describes would to 
apply only in the case of third-party gametes and embryos. 
   
                                                 
74
 Jon Havelock et al. 2016. Canadian Fertilization and Andrology Society Guidelines for Third Party Reproduction. 
Montreal: Canadian Fertilization and Andrology Society. at 2, Glossary; The Province of Ontario sidesteps the use 
RIWKHWHUPµGRQRU¶E\PDNLQJWKHDFWLRQRIGRQDWLRQRIUHSURGXFWLYHPDWHULDODQHJDWLYHDFWLRQDVLWFRQFHUQV
parentage.All Families Are Equal Act (Parentage and Related Registrations Statute Law Amendment), 2016, S.O. 
2016, c. 23 at:  s.5(1) A person who provides reproductive material or an embryo for use in assisted reproduction, 
(a)  is not, by reason only of the provision, a parent of the child; and (b)  shall not, by reason only of the provision, 
be recognized in law to be a parent of the child. 
75
 2017 CAN/CSA Standards Council of Canada supra note 12 at 17.  
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Yet, if we look closely at the 2017 CAN/CSA 6WDQGDUG¶Vdefinition of donor, we realise that it is 
PRUHQXDQFHGWKDQLWDSSHDUVRQILUVWUHDGLQJ$VWKHHPSKDVLVLVRQµSURYLGLQJ¶UHSURGXFWLYH 
tissues for use in a recipient who is not his/her own spouse, common-law partner of sexual 
partner, the case of sperm provided by the intended father and used to fertilise the ovum 
provided by the traditional surrogate would need to be screened and tested. But it is not clear that 
WKH6WDQGDUG¶VGHILQLWLRQfully encompasses the situation of ovum provided by a traditional 
surrogate as she would be using her own ovum. Yet, the AHRA at s.10(2)(c) mandates screening 
DQGWHVWLQJRIWKHWUDGLWLRQDOVXUURJDWH¶VRYXPZKHQXVHGLQKHURZQSUHJQDQF\ 
 
These FRQIOLFWLQJGHILQLWLRQVRIµGRQRU¶ZKHQDSSOLHd to the woman who agrees to have an ovum 
obtained and who also agrees to use this obtained ovum in her own surrogate pregnancy create a 
number of worrisome implications for conditions of authorised use and for consent to use. 
)LUVWO\E\PDNLQJHYHU\SHUVRQLQYROYHGLQDVVLVWHGUHSURGXFWLRQDµGRQRU¶UHJDUGOHVVRI
whether the acWLYLW\LQYROYHVµRZQXVH¶RUµWKLUG-SDUW\XVH¶WKH$+5$VLWXDWHs the obtaining and 
using of sperm and ovum as a prohibited medical fertility technology unless expressly permitted 
by regulation.   
 
Second, in the case of traditional surrogates given that they use their own ova in their own 
VXUURJDWHSUHJQDQF\WKHDFWRIµREWDLQLQJ¶DQRYXPDSSHDUVWREOXUWKHOLQHEHWZHHQµRZQ¶ use 
DQGµWKLUG-SDUW\¶XVH7KHSUREOHPEHFRPHVIXUWKHUHQWDQJOHGZKHQRQHYLHZVthe concept of 
µXse¶ WKURXJKWKHOHQVRIµSDWLHQW¶rather than µdonor¶. Common law requires that medical 
patients provide consent to treatment. The AHRA speaks not of patients, but of donors.  The 
2017 CSA Standard adds another dimension by referring to a µdonor¶ who provides human 
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reproductive material to be used by a recipient who is not a spouse, common-law or sexual 
partner. It conveniently omits a reference to WKHµREWDLQHG¶RYDXVHGE\WKHZRPDQLQKHURZQ
pregnancy, including her own surrogate pregnancy. On a face-value reading of the 2017 
CAN/CSA Standard definition, the case of a WUDGLWLRQDOVXUURJDWHZKRSURGXFHGWKHµREWDLQHG
RYD¶DQGZKRLVDOVRWKHUHFLSLHQWRILWDSSHDUVnot to be captured within the scope of the 
definition.  <HWWKH$+5$UHTXLUHVKHUµREWDLQHG¶RYDWREHVFUHHQHGDQGWHVWHG 
 
The definition RIµGRQRU¶matters for our examination of the changes made to s.10 of the AHRA. 
It sets the dividing line separating autologous and own-use donation as these are instances where 
the gametes can be used without the need for screening and testing whereas screening and testing 
RIµWKLUG-SDUW\¶KXPDQUHSURGXFWLYHPDWHULDOis mandated under the Criminal Code. Failure to 
test and screen bears a criminal code penalty.  I argue that the requirement specified at s.10(2)(c) 
transforms autologous use LQWRDµWKLUG-SDUW\¶DFWLYLW\WKRXJKRQO\IRUWUDGLWLRQDOVXUURJDWHV In 
so doing, the AHRA and ensuring regulations situate the traditional surrogate as a third-party 
donor who poses a health and safety threat, though to whom is not clear.  
 
This sleight of hand whereby the traditional surrogate is both third-party ova donor and surrogate 
who uses her own ovum distances her from the role of a fertility patient who uses her own 
gametes. We see this repositioning very clearly in how assisted reproductive data are reported. 
For example, Canadian and American fertility clinics record gestational surrogates as receiving 
embryos containing either µRZQXVH¶RUµWKLUG-SDUW\¶RYD,QDOOFDVHVwhere a gestational 
surrogate receives an embryo labelled µRZQXVHRYD¶ it is in fact the LQWHQGHGPRWKHU¶VRYD that is 
being used.  This occurs because the clinics consider the intended mother to be the fertility 
   
 20 
patient not the gestational surrogate.76  A similar reimagining occurs in the amendment 
at10(2)(c). By turning a traditional surrogate into a third-party donor, I argue, that her ability to 
determine to decide the use of her obtained ova will be constrained especially if it translates into 
KHUIRUPDOO\µGRQDWLQJ¶KHURYXPWRWKHLQWHQGHGSDUHQWV,QWKLVUHJDUGWhe implications for 
mandatory screening and testing set out in s.10 and the obligations imposed by the Section 8 
(Consent) Regulations given her newly acquired status as third-party donor are significant.  
 
From which type of donor is sperm and ova to be screened and tested?  
To better understand the implications of the proposed regulatory regime we need to examine 
which type of donor and donation triggers mandatory screening and testing. 
 
Sperm donors 
At s.10(2)(a), unless µobtained¶ sperm is to be used b\WKHGRQRU¶VVSRXVHFRPPRQ-law or 
sexual-partner, it must be tested and screened pursuant to the criteria established by s.10(3). In 
principle, the approach represents no change to existing law.  
 
In response to the use of untested sperm that resulted in the unfortunate transmission of HIV77 all 
human sperm used by WKHSHUVRQRWKHUWKDQWKHGRQRU¶VVSRXVHFRPPRQ-law or sexual partner or 
imported for third-party reproductive use must comply with the Health Canada screening and 
                                                 
76 See article written by Kiran M Perkins et al. 2016. ³7UHQGVDQGRXWFRPHVRIJHVWDWLRQal surrogacy in the United 
States´. Fertility and Sterility 106: 435.  The analysis undertaken is conducted from the perspective of the intended 
parents as they are viewed by the fertility industry to be the patients with the result that very little information is 
obtained about the surrogate undergoing the embryo transfer or pregnancy. 
77
 ter Neuzen v. Korn [1995] 3 S.C.R. 674; Araneta, MR, Mascola  L, Eller  A, O'Neil  L, Ginsberg  MM, 
Bursaw  M, Marik  J, Friedman  S, Sims  CA, Rekart  ML.  1995. ³+IV transmission through donor artificial 
LQVHPLQDWLRQ´ Journal of the American Medical Association  273(11): 854-8;  
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testing standard instituted in 1996.78  The sperm testing regulations were further tightened in 
2000 after a woman contracted chlamydia trachomatis from an infected donor.79 
  
The text of the screening and testing amendment at s.s.10(3)(a) and (b) echo the procedures 
mandated in the 1996 Semen Regulation,80 specified in the 2000 Technical Requirements 
Directive,81 and explained in the Guidance82 document.  It is these technical conditions83 for the 
screening, testing and labelling of human sperm that are under review as part of the Health 
Canada regulation exercise.84 The 2017 CAN/CSA Standard85 specifies criteria for donor 
suitability and sets out the required elements for donor selection and the screening and testing 
regime to be applied to anonymous and designated reproductive donors. Compared to the 1996 
Semen Regulation and related Directive, the restrictions imposed on µDesignated Reproductive 
Donors¶ have been relaxed and the scope for designating a known donor have been widened. A 
Directed Reproductive Donor is defined in the 2017 CAN/CSA Standard as: 
 ³DSHUVRQZKRLVWKHVRXUFHRIUHSURGXFWLYHFHOOVRUWLVVXHV>LQFOXGLQJVHPHQRYDRU
embryos (to which the donor contributed the spermatozoa and ovum) to a specific 
recipient, and who knows and is known by the recipient before donatiRQ´ 
 
Notes:  
1) This term does not include a sexually intimate partner. See Donor. 
                                                 
78
 Processing and Distribution of Semen for Assisted Conception, SOR/96-254. May 7, 1996.  
79
 Health Canada. Directive Technical Requirements for Therapeutic Donor Insemination, July 2000; 
Alana Cattapan & Fran9RLVH%D\OLV³7KH7URXEOH:LWK3D\LQJ)RU6SHUP³. Toronto Star. April 9, 2016. 
https://www.thestar.com/opinion/commentary/2016/04/09/the-trouble-with-paying-for-sperm.html 
80
 Processing and Distribution of Semen for Assisted Conception, SOR/96-254. May 7, 1996 
81
 Health Canada. Directive Technical Requirements for Therapeutic Donor Insemination, July 2000. 
82
 Health Canada. Guidance on the Processing and Distribution of Semen for Assisted Conception Regulations 
(Guide-0041).  
83The existing standard is controversial especially for male donors who have sex with males and for designated 
donors.  See: 6WX0DUYHO³³7RQ\'DQ]D³,V0\6SHUP'RQRU"´4XHHU.LQVKLSDQGthe Impact of 
&DQDGLDQ5HJXODWLRQVDQG6SHUP'RQDWLRQ´Canadian Journal of Women and the Law 25(2): 221 
84
 See comments in 2018 Health Canada consultation report summary: ³:KDW:H+HDUG´ 
85
 Standards Council of Canada. CAN/CSA-Z900.2.1-17 Tissues for assisted reproduction. December 2017 at 10. 





The designated reproductive donors is not a donor type identified in the AHRA though this type 
of donation has been a contested feature of the assisted human reproduction landscape since the 
1996 Semen Regulations were enacted.87  The 2017 CAN/CSA Standard, like the Act at 10(2)(a), 
would require in the case of surrogate recipients that the sperm of the intended father be screened 
and tested for sexually communicable diseases.  Given that gestational and traditional surrogates 
will know the sperm donor (intended father) it is expected that the Designated Reproductive 
Donor schema for testing and screening would apply. The 2017 CAN/CSA Standard also 
recommends that surrogates receiving directed human reproductive material (sperm, ova and 
embryos) be provided with additional counselling about the risk associated with waiving the 
post-quarantine tests for infectious diseases.88  This is a prudent recommendation given US 
research findings showing that only 75% of gestational surrogates receive counselling.89 The 
proportion Canadian surrogates, gestational and traditional, who receive counselling is not 
known. The Section 8 (Consent) Regulations does not mandate counselling and the provinces 
would likely assert that counselling of fertility patients falls within their constitutional sphere of 
responsibilities.  Apart from Quebec,90 provinces have not sought to enact fertility treatment 
                                                 
86
 Standards Council of Canada, CAN/CSA-Z9000.2.1-17. Tissues for assisted reproduction. December 2017 at 17.  
This is an interesting definition and it could be argued that it leaves open the possibility artificial gametes and 
SHEEFS to be created from designated reproductive donors.  
87
 Marvel, 2013.  supra note 5. 
88
 Standards Council of Canada. CAN/CSA-Z900.2.1-17 Tissues for assisted reproduction. December 2017, section 
17.3.1 at 62. 
89
 Erika L. )XFKV	$EE\%%HUHQVRQ³6FUHHQLQJRIJHVWDWLRQDOFDUULHUVLQWKH8QLWHG6WDWHV´Fertility and 
Sterility, 106: 1496-1502. 
90
 An Act respecting clinical and research activities related to assisted procreation, CQLR.C-A-5.01; Bill 20, (2015, 
chapter 25) An Act to enact the Act to promote access to family medicine and specialized medicine services and to 
amend various legislative provisions relating to assisted procreation. 10 November 2015. See amendments at s.10 
regarding delivery of services and drawing up of ethical and safety guidelines by Collqge des mpdecins du Qupbec.  
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legislation though the 2016 Ontario, All Families are Equal Act, requires that surrogates and 
intended parents had a legal arrangement in place.91  
      
 
 
Ova donors  
The 2012 amendments of the AHRA at1 s.10(2)(b) specify that all human ovum used for human 
reproduction must be screened and tested unless it is to be used by the µdonor¶ or by the µGRQRU¶V
spouse, common-law or sexual partner¶.  However, at s.10(2)(c), if the µdonor¶ plans to use her 
own obtained ovum in her own surrogate pregnancy, it must be screened and tested even though 
it will be returned by means of a uterine transfer to the donor. It is worth recalling that in Ref re 
AHR, Justices Le Bel and Deschamps took the view that not all public health risks should be 
DGGUHVVHGWKURXJKFULPLQDOODZ³LWPXVWEHIRXQGWKDWWKHUHLVDQHYLOWREHVXSSUHVVHGRU
prevented´92 What can explain the possible health harm that could occur to a woman using her 
own ovum in her own surrogate pregnancy that would not also arise when the woman used her 
own ovum or the ovum of her spouse, common-law or sexual partner in her own non-surrogate 
pregnancy?  
 
On first inspection, the 2012 AHRA amendment mandating screening and testing of ova used in 
third-party reproduction corrects a long-standing legislative omission identified by Rivard and 
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Hunter93 who recommended in 2005 that the government take steps to regulate health and safety 
measures for human ova used in third-party reproduction. Certainly, changes within the practice 
of fertility medicine had evidenced strong demand for third-party donated ova along with 
dramatic improvements in the techniques used to cryopreserve ova.  Moreover, preservation of 
the ova is no longer an unproven or experimental technique with research failing to demonstrate 
superior outcomes using fresh oocytes (ova) over that of vitrified egg-banked oocytes.94   
 
Canadian clinicians have welcomed this long overdue legislative change requiring testing and 
screening of ova used by third-parties.95  It is a regulatory modification that the federal agency, 
Assisted Human Reproduction Canada, could have brought into force prior to its demise in 2012 
had it used its mandate to protect the health and safety of Canadians. But it did not.96  
 
The Standards Council of Canada 2017 CAN/CSA standard provides guidance for the screening 
and testing of third-party ova donors: anonymous and directed.97 It establishes the screening 
criteria for donation which includes the recording of WKHGRQRU¶Vfamily genetic history, medical 
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testing for diseases, and establishes the criteria for donor suitability evaluations.98  As noted, it is 
likely that these elements will be adopted by Health Canada in its upcoming regulatory project.99  
 
The 2012 amendment at 10(2)(b) also FODULILHVLQODZWKDWWKHXVHRIDSDUWQHU¶VRYum by a 
woman in same-sex married, common-law and sexual relationships is to be exempt from 
screening and testing. This type of ova sharing (co-mothering) among lesbian partners is not 
unknown nor uncommon, though no Canadian data exists as to its prevalence.100 Yet, one needs 
to ask why Canadian legislators felt it necessary to explicitly specify that this type of 
reproductive tissue exchange was permitted and that the reason for its non-prohibition is one of 
health and safety.  The AHRA at s.3 states that discrimination in assisted reproduction is 
prohibited.  Surely if heterosexual partners are permitted to exchange sperm and use their own 
ova, it not clear why the same logic did not automatically apply to the exchange of ova between 
lesbian spouses, common-law and sexual partners. 
 
For other nations, issues interfering with lesbian exchange of ova have included assisted 
reproduction access restrictions based on sexual orientation and marital status alongside an 
ethical discourse suggesting that the medical surgery needed to remove ova from one partner to 
give to another when both were fertile was unnecessary and as such could be considered 
                                                 
98
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99
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maleficent.101 Currently, the legality of the practice varies considerably across Europe, 
depending on the legal recognition of same-sex marriage and partnership with countries like 
Belgium, Finland, Ireland, Netherlands, UK, Portugal and Spain permitting it while others such 
France or Germany prohibiting or actively discouraging it.102 In places where family law has 
been changed for example, in the UK when the Human Fertilisation and Embryology Act was 
amended in 2008 to remove the need for a father and lesbian partners permitted to become legal 
parents, the practice has become more common. In the UK, the issue now revolves on ensuring 
that all parties exercise informed consent rather than in regulating the health and safety of the 
practice.103  
 
By not imposing prohibitions regarding the use by a fertility patient of the ova donated by her 
spouse, common-law or sexual partner,104 &DQDGD¶V$+5$VHHNVWRnormalize same-sex female 
relationships.  It accords the exchange of ova between female spouses, common-law and sexual 
partners an equivalency status with autologous ova used by a woman in a heterosexual married, 
common-law or sexual relationship. Specification that the sharing of ova between women 
engaged in a same-sex spousal, common-law or sexual relationship also serves to note that the 
federal government considers that the practice holds a no greater health risk to the lesbian 
recipient than would be experienced to exist for any other woman using her own ova or in the 
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case of a heterosexual women from receiving a transfer of sperm obtained from her male spouse, 
common-law or sexual partner.  
 
However, the reason for allowing equal treatment for the use of shared gametes among spouses, 
common-law and sexual partners regardless of sexual orientation, as noted in the preamble to the 
screening and testing amendment is a permission reliant on a health and safety rationale105 rather 
than legal equivalency106 and the right to equal treatment.107 As was ruled by the SCC in 
Andrews v. Law Society of British Columbia ³discrimination may be described as any 
GLVWLQFWLRQFRQGXFWRUDFWLRQZKHWKHULQWHQWLRQDORUQRWEXWEDVHGRQDSHUVRQ¶VVH[XDO
orientation, that has the effect of either imposing burdens on an individual or group that are not 
imposed upon others, or withholding or limiting access to opportunity, benefits and advantages 
DYDLODEOHWRRWKHUPHPEHUVRIVRFLHW\´108 Equally, the amendment could have referenced the 
principle of non-discrimination that underlies Canada¶VAHRA³SHUVRQVZKRVHHNWRXQGHUJR
assisted reproduction procedures must not be discriminated against, including on the basis on 
WKHLUVH[XDORULHQWDWLRQRUPDULWDOVWDWXV´109 But, it did not.  
 
It is unfortunate that the government did not use the 2012 legislative opportunity to indicate that 
co-motherhood assisted reproduction has been permitted since the inception of the AHRA 
notwithstanding any stated ethical concerns advanced by those arguing that intra-couple egg 
sharing for nonmedical reasons could be considered to be ethically non-justifiable, risky, and not 
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cost-effective.110  Such argumentation is weak and profoundly dismissive of the reproductive 
autonomy of lesbians.111 Moreover little empirical research exists to support claims that the 
practice is any more risky compared to the harm endured by other female patients undertaking 
ovarian stimulation related to third-party ova donation or for their own reproductive use. 112  This 
is an example of where the federal government has embedded a health and safety justification for 
permitting co-mothering and the exchange of ova between lesbian spouses and common-law and 
sexual partners rather than adopting an equality-based rationale as enabled by s.3 of the Act.  
 
Traditional surrogates 
The amendment at s.10(2)(c) created another group of regulated autologous ova users:  
traditional surrogates.113  We need to assess whether the supposed health harm of a woman using 
DQXQVFUHHQHGDQGWHVWHGRZQµREWDLQHG¶RYDLQKHURZQVXUURJDWHSUHJQDQF\warrants 
prohibition under the criminal code.  We also need to question the legal basis whereby the status 
of the µobtained¶ ovum has been seemingly transformed from that of an autologous tissue that 
poses no health harm to the woman from whose body it originated to that of DµWKLUG-SDUW\¶RYD
which KDYLQJEHHQµREWDLQHG¶somehow presents a health and safety risk.  In order to situate this 
GLVFXVVLRQZHQHHGWRUHYLHZ&DQDGD¶VSRVLWRQRQOHJDOLW\RIVXUURJDF\ especially given that the 
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law views surrogacy when undertaken for payment is seen to constitute a moral evil. Though as 
Millbank asserts, surrogacy in Canada straddles a non-commercial/commercial boundary.114  
 
Surrogacy: µMoral evil¶  
The AHRA establishes that surrogacy is legal in Canada as long as it done altruistically.115 Both 
forms, traditional surrogacy where the surrogate is genetically related to the child she bears for 
intended parent(s) and gestational surrogacy, where the surrogate is not genetically related to her 
offspring, are permitted.  
 
The practice of a woman conceiving and carrying a child for an individual or couple who for 
medical or social reasons are unable to have their own children has been characterised as morally 
troubling as it disrupts the normative view of motherhood.116 It has been a controversial topic for 
Canadians.117 Certainly concerns about commercialisation of human reproduction, the practice of 
traditional surrogacy, DQGWKHµPRUDOSDQLF¶UDLVHGE\WKH%DE\0incident cast a long 
shadow over the deliberations of assisted reproduction undertaken by Baird Commission, 
Parliamentary Committees, and parliamentarians.118 The banning of commercial surrogacy by 
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the AHRA conformed to the national narrative privileging unpaid donation of blood, organs and 
tissues and reflected a desire on the part of regulators to avoid an American style approach to the 
practice of fertility medicine.119  
 
However, considerable social change has taken place in Canada since the 1983 Baird 
Commission held public consultations on the topic of assisted reproduction, including surrogacy. 
Twenty-first century Canada has legalised same-sex marriage,120 Quebec funded IVF surrogacy 
costs121 and since 2016, Ontario pays for gestational and traditional surrogates to receive fertility 
treatment.122 Gradually provincial governments have been updating family law statutes to reflect 
parentage made possible by assisted conception, including traditional and gestational 
surrogacy.123 
 
It is not surprising that there now exists growing evidence that for an increasing number of 
childless Canadian couples and individuals including gay men, surrogacy may be the only way to 
have biological children.124 For example, a 2012 survey revealed that one-quarter of Canadian 
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childless adult women and 40 percent of childless adult men would consider using a surrogate 
should they or their partner be unable to carry and give birth to their biological child.125 It is not 
uncommon to read news articles detailing surrogacy experiences told from various 
perspectives.126 Moreover, research with North American surrogates demonstrates, they are 
typically middle-class, college educated, heterosexual married women who have had non-
problematic pregnancies and who undertake the practice for altruistic reasons regardless of the 
commercial/non-commercial regime in which they operate.127  
 
Given this emerging acceptance of gestational and traditional surrogacy, it is difficult to support 
the view that a moral evil rationale could be the justification for imposing a prohibition on the 
use of unscreened and untested obtained own-use ova used by an altruistic traditional surrogate 
in her own pregnancy. The reason must be the one that as stated in the preamble to the 
amendment: health evil. The question that needs to be answered: To whom does this harm occur?  
 
 
IDENTIFYING THE HEALTH EVIL EMBODIED IN THE µ2%7$,1('¶2980
µ'21$7('%<$:20$1$1'86(',1+(568552*$7(35(*NANCY  
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The AHRA as amended at s. 10 applies criminal law sanctions to address the µhealth and safety 
evils¶ posed by a ZRPDQ¶VRZQ µobtained¶ ovum being used in her surrogate pregnancy.  Let us 
now attempt to determine what might be the health and safety risks posed by µobtained¶ 
traditional surrogate ovum to ascertain whether use of unscreened and untested obtained 




Health and safety risks to the traditional surrogate 
Does the use of their own untested and unscreened ova jeopardize the health and safety of 
traditional surrogate patient? It is illogical to suggest that a traditional surrogate using her own 
ova in her pregnancy faces a greater health risk than do other women who use their own ova or 
the ova of their spouse or common-law or sexual partner in their own pregnancy.  Recent 
findings show that gestational surrogates using donor ova appear to experience more adverse 
prenatal and birth delivery outcomes compared to their previous birth experiences where 
conception was achieved without use of in vitro fertilization which is the usual situation 
practiced by traditional surrogates.128    
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It can be argued that the concern about the health harm to the traditional surrogate of using her 
own µREWDLQHG¶ovum in her surrogate pregnancy is misplaced as it is WKHDFWRIµREWDLQLQJ¶WKH
ova through the application of ovarian stimulation that poses the actual health risk. Ovarian 
hyper-stimulation syndrome (OHSS) is a serious treatment complication; one which could result 
in patient death. While it is thought to affect about 1.8% of all IVF cycles129 it nonetheless 
represents one the most important concerns in modern IVF practice.130  It should be noted that 
OLWWOHWRQRVWXG\RI&DQDGLDQIHUWLOLW\SDWLHQWV¶H[SHULHQFHRI2+66KDVEHHQFRQGXFWHGDQGWKH
DQQXDOUHOHDVHRIOLPLWHGLQIRUPDWLRQIURPWKH,9)'LUHFWRUV¶DVVLVWHGKXPDQUHSURGXFWLRQ
registry (CARTR-Plus) provides minimal insight on the occurrence of this etiology in Canadian 
fertility clinics.131 
 
What is in doubt then is why it would be thought that a more serious health harm would accrue 
to a traditional surrogate compared with other fertility patients who undergo ovarian stimulation 
to obtain ova. A matter worthy of our examination I suggest is the potential for confusion about 
who has the authority to make decisions about the use of the µREWDLQHG¶embryo. For example, a 
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mix up or failure on the part of the IVF clinic to acquire written and informed consent regarding 
the creation of an embryo containing this ovum and its use could present a moral and legal harm 
to the traditional surrogate.¶ 
 
Given the above analysis, one must conclude that the health and safety risk to traditional 
surrogates of using their own ova cannot be the reason for mandatory screening and testing of 
obtained ova as it fails to meet the harm test established by the SCC in Ref re AHR.  
 
Health and safety risks to clinic staff and patients  
Most human sperm, ova, and embryos used and stored in IVF clinics are own use in that they 
have been provided by the fertility patient and their spouse, common-law or sexual partner and 
will be used in their fertility treatments.132  Own use gametes and embryos are not subject to 
mandatory screening and testing though fertility patients, spouses and partners and will undergo 
a series of medical tests including ones capable of detecting the existence of sexually transmitted 
diseases and to reduce the risk of transmission of disease.133   
 
All Canadian fertility clinics have been encouraged to follow human reproductive material and 
embryo labelling, handling and storage protocols designed to prevent cross-contamination and 
misidentification.134  It appears that Canadian IVF clinics have voluntarily adopted the 
                                                 
132
 Data from the Canadian Assisted Human Reproduction Technology Registry CARTR-Plus show that 95% of IVF 
patients use their own gametes. See 3DPHOD0:KLWH³Hidden from view: Canadian gestational surrogacy 
practices and outcomes, 2001-´ Reproductive Health Matters, 2016. 24: 203. 
133
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procedures and protocols developed by the Standards Council of Canada to prevent 
contamination and mislabelling though to date no monitoring information informs Canadian 
consumers about compliance.135 It is recommended that fertility clinics ensure that Standard 
Operating Procedures are in place to address health and safety requirements regarding sperm, 
ova and embryo preparation and preservation136 and packaging, storage, and the cleaning and 
maintenance of cryopreservation tank containers.137  
 
In light of the above, it is difficult to sustain the argument that unscreened and untested ova 
obtained from a traditional surrogate represent a risk to IVF clinic staff and other patients 
sufficient to warrant criminal law sanctions criminalising a failure to screen and test. Thus, the 
expectation that ova obtained from a traditional surrogate poses significant health risks to the 
routine operation of IVF clinics or to other patients cannot be the rationale for the imposition of 
mandatory testing and screening.   
 
Health and safety risks to children born to traditional surrogates 
The preamble to the AHRA includes a section setting out ethical principles guiding the practice 
of assisted reproduction in Canada. The importance of beneficence and non-malfeasance in the 
practice of fertility techniques underscores s.2(a) of the Act whicKVWDWHV³The health and well-
being of children born through the application of assisted human reproductive technologies must 
EHJLYHQSULRULW\LQDOOGHFLVLRQVUHVSHFWLQJWKHLUXVH´138  In light of this concern, can one sustain 
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 Canadian Standards Association Standard CAN/CSA Z900.2.1-17 Tissues for assisted reproduction, December 
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the argument that it is the public good desire to minimize potential health and safety risks to the 
offspring of traditional surrogates that supports the rationale and justification for mandatory ova 
screening and testing?  
 
Traditional and gestational surrogates who receive treatment at Canadian fertility clinics are 
tested to establish their communicable disease status and to assess their ability to successfully 
conceive and bear children. The voluntary Third-party reproduction guidelines developed by 
Canadian Fertility and Andrology Society139 apply regardless of the fertility treatment a 
surrogate may receive²ovarian stimulation, IVF embryo transfer, and artificial insemination. 
However, the federally mandated screening and testing of traditional surrogates triggered by an 
µobtained¶ traditional surrogate ova being produced as result of ovarian stimulation, a procedure 
that carries known risks implies that a different set of procedures, are to apply. This occurs 
because the Act in effect repositions the status of obtained traditional surrogate ovum and 
reimagines it to be µdonated¶ third-party ovum, even though it will be used by the traditional 
surrogate in her own surrogate pregnancy. A missing piece of this puzzle concerns her ability to 
retain use control over these obtained ova. However, in this discussion we need to recall that the 
prime reason for screening and testing of human reproductive material is prevent the 
transmission of disease to a third party; that is, someone other than the person who provided it.  
 
%\WUHDWLQJWKHµREWDLQHG¶WUDGLWLRQDOVXUURJDWH¶RYDDVthird-party-donated human reproductive 
material, the amended Act proposes to impose at s.10(3) testing and screening protocols similar 
to those described in Processing and Distribution of Semen for Assisted Conception 
                                                 
139Jon Havelock et al. 2016. Guidelines for Third Party Reproduction. Montreal: Canadian Fertility and Andrology 
Society at 24.  
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Regulations140 and Work-Up of the Directive on Technical Requirement for Therapeutic Donor 
Insemination.141 In the 2017 CAN/CSA Standard we can see how these conditions would be 
operationalised.  For example, the medical, personal and family history information about the 
traditional surrogate would be obtained and donor suitability screening undertaken.142 It would 
appear that a more intensive set of screening and disease detection tests would be instituted143 
compared with the voluntary system of screening and testing guidelines proposed by the 
Canadian Fertility and Andrology Association for traditional surrogates undergoing artificial 
insemination.144  
 
It should be noted that the AHRA does not mandate that medical, personal and family history 
information be obtained from a gestational surrogate. Thus, there is a strong likelihood that an 
uneven collection of personal information is likely to occur as more personal health data and 
medical history information will be acquired in the isolated and rare instances where ova of a 
traditional surrogate are obtained. 
 
Regulated screening and testing of a traditional surrogate for communicable health conditions 
and documentation of medical, genetic and family history would provide additional health and 
safety assurances to commissioning parents that the surrogate-related child would not be prone to 
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serious health or genetic conditions inherited from the traditional surrogate. Acquisition of 
obtained ova also enables preimplantation genetic diagnosis (PGD) and karyotyping, processes 
that permit detection of genetic defects and anomalies including trisomy and determination of 
risks for serious genetic disease.145  
 
If testing and screening documentation obtained as result of screening and testing was made 
available to surrogate-born children, they would have potentially crucial information about their 
genetic parentage and medical history. It should be noted that the AHRA does not mandate that 
medical, personal and family history information be obtained from a gestational surrogate nor 
when traditional surrogacy is undertaken using assisted insemination, which is the more common 
practice. Thus, there is a strong likelihood that an uneven collection of personal information is 
likely to occur as more personal health data and medical history information will be acquired in 
the isolated and rare instances where ova of a traditional surrogate are obtained.  
 
Without a donor registry there exists no formal means for a donor-conceived child or a 
traditional surrogate conceived child to learn about their biological parents.  Without parental 
disclosure no mechanism exists enabling them to know that they were a surrogate-born child or 
that sperm or ova have been provided by persons other than their social (intended) parents. Such 
information could be of health importance especially as our understanding of the implications of 
epi-genetic phenomena increases and in cases where inherited biological traits may have medical 
and health consequences.  
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&DQDGD¶Vfederal donor registry, as envisaged by the AHRA,146 was ruled ultra vires by the 
Supreme Court. Provincial gamete and embryo donor registries do not exist. Submissions made 
to Health Canada as part of the consultation on regulatory change have identified a need for 
them.147   Given that no Canadian donor registry exists, no organised and managed system will 
enable the offspring of traditional surrogates to access the information obtained as a result of a 
screening and testing regime.148 As the decision in Pratten v British Columbia demonstrates, 
knowing RQH¶VJHQHWLFKLVWRU\ is not a constitutional right.149  Information indicating that one has 
been conceived using donor sperm and/or ova is not is recorded on birth registration forms 
though it could be were Canadian provinces to follow the example set by the US states of 
Massachusetts, Florida, Michigan and Connecticut.150 However to do so would involve 
legislative change. The BC Vital Statistics Act, for example, prevents the birth registration 
recording of AHR conception.151 In other provinces, the vital statistics legislation is silent on the 
matter though the activities of the Uniform Law Commission provide the opportunity to consider 
this option for Canadian provinces to consider.152 In the absence of intended parents providing 
information about donors and surrogates, traditional surrogate-born children, like gestational 
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surrogate-born children and other donor-conceived children, must look elsewhere to locate donor 
profile information and siblings; for example, sperm and ova banks, the IVF clinic that 
performed the treatments, and the Donor Sibling Registry.153  
 
Research shows that surrogates bond with intended parents154 and findings from UK studies 
demonstrate that gestational and traditional surrogates, intended parents, and surrogate-born 
children can maintain positive and supportive post-birth relationships.155 In Canada, given the 
lack of a donor registry, the maintenance of relationships with intended parents between 
surrogates takes on heightened importance as this may be a key way for the traditional surrogate-
born child to know about its genetic background. 
 
Given that mandatory testing and screening will occur only for µobtained¶ ova, why does a health 
and safety µevil¶ warranting criminal law sanctions benefit only the children conceived using ex 
utero traditional surrogate ova? If non-malfeasance is the rationale invoked for application of 
criminal law powers, surely it is owed to all offspring of traditional surrogates, regardless of the 
location of the ova at time of conception.156 The amended AHRA represents, at best, a limited 
interpretation of compassion for the donor-conceived. 
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+HDOWKDQGVDIHW\KDUPRIDQµREWDLQHG¶WUDGLWLRQDOVXUURJDWH¶VRYXP 
On careful examination, it is difficult to determine how the ovum obtained from a traditional 
surrogate and used in her own pregnancy represents a health and safety harm so significant as to 
justify the application of criminal code sanctions on those who would fail to screen and test it 
prior to its use.  This paper¶V findings support the conclusion that the application of criminal 
code sanctions used to penalise those who would fail to screen and test the ova fails to meet the 
test laid out by the SCC in Ref re AHR.  
 
I argue that not only does the amendment fail to meet the test needed for the application of 
criminal code penalties, the imposition of mandatory screening and testing imposes a harm: re-
LPDJLQLQJRIWKHVXUURJDWH¶VRYD7KHDPHQGPHQWIXQFWLRQVWRWUDQVIRUPLWIURPDXWRORJRXVXVH
to third-party use. The implications for consent, reproductive autonomy of traditional surrogate 
and for fertility patients is considerable. 
   
IMPLICATIONS FOR TRADITIONAL SURROGATES OF AHRA AMENDMENTS 
CONCERNING THE TESTING AND SCREENING OF OVA  
 
The Act by requiring screening and testing the testing and screening of an obtained ova donated 
by a woman and used in her surrogate pregnancy DSSHDUVWRWUDQVIRUPDWUDGLWLRQDOVXUURJDWH¶V
ova by means of law and regulation LQWRDµthird-party¶ body part notwithstanding her genetic 
affinity to it or that once transferred back to her, it will be her decision during the pregnancy and 
on the birth of the child to fulfil or not to fulfil the surrogacy arrangement. To further muddy the 
waters, the GHILQLWLRQRIµGRQRU¶DGRSWHGE\WKH2017 CAN/CSA Standard excludes autologous 
use DVLWGHILQHVµGRQRU¶DVEHLQJ³DQLQGLYLGXDOZKRSURYLGHVUHSURGXFWLYHWLVVXHVIRUXVHLQD
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recipient who is not his or her spouse, common-ODZRUVH[XDOSDUWQHU´157  This definition implies 
WKDWWKHDXWRORJRXVXVHULVQRWDµGRQRU¶+RZHYHU, the AHRA amendment at s.10 mandates that 
the surrogate who agrees to have her ova removed from her body by ovarian stimulation must 
submit herself and the ova to testing a screening as specified in regulation. The obvious work 
DURXQGWKH$+5$¶VLPSRVLWLRQRIULJRURXVVcreening and testing is to qualify her as a 
³GHVLJQDWHGUHSURGXFWLYHGRQRU´XQGHUWKHCAN/CSA Standard even though she does not 
fit the 6WDQGDUG¶Vdefinition of a donor.   
 
It is also important to note that the act of obtaining an ovum from a traditional surrogate is rare. 
Neither the US nor the Canadian assisted reproduction registries provide information on 
traditional surrogacy undertaken using assisted insemination or IVF.158 The Ontario Fertility 
Program began funding IVF and assisted insemination for surrogate patients in 2016.  Under the 
program, it is possible for a woman who has been or plans to be a surrogate (traditional or 
gestational) to receive to receive ovarian stimulation for her own fertility uses. The program does 
not prevent her from uVLQJKHURZQµREWDLQHG¶RYDLQKHURZQWUDGLWLRQDOVXUURJDWHSUHJQDQF\ 
 
Regrettably the Ontario program does not track surrogate treatments, with the result that no 
information is available on the uptake of this program by these patients or the outcomes.159 Nor 
is it possible to obtain a count of the number of traditional surrogates undergoing screening and 
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testing using CAN/CSA designated reproductive donor option. Nor is possible to track the 
WUDQVIRUPDWLRQRIVWDWXVIURPµRZQ¶RYDWRWKDWRIµGRQDWHGRYD¶DQGWRXQGHUVWDQGWKHORVVRI
control over its use and change in consenting that such a reimagining of ovum entails.  Finally, 
WKH2QWDULRSURJUDPFRQVLGHUVµJHVWDWLRQDODQGWUDGLWLRQDOVXUURJDWHVWREHSDWLHQWV., though the 
clinic which undertakes the tUHDWPHQWUHIHUVWRWKHLQWHQGHGSDUHQWVDVWKHµIHUWLOLW\SDWLHQWV¶DQG
the data collected on the treatments involving the surrogate (traditional and gestational) is 
recorded from the perspective of the intended parent. I would argue that that the existing data 
recording system will likely label the ova provided by a traditional surrogate and used in her won 
pregnancy as a third-SDUW\GRQRUJDPHWHUHJDUGOHVVRIZKHWKHUVKHKDVFRQVHQWHGWRµGRQDWH¶LWWR
the intended parents for their reproductive uses.  
 
Twisted and muddled terminology about who is the fertility patient and how this differs in 
federal and provincial law and clinic practice reveals the potential for problems in the area of 
consent to use and consent to treatment, especially when roles become interchangeable. While no 
data are collected on Ontario traditional surrogates using their own obtained ova, the practice can 
and does occur as the case of a BC traditional surrogate, Ms Chonn, recently revealed.   
 
Ms. Chonn had acted as a traditional surrogate for intended parents. In so doing she had had 
undergone ovarian stimulation and agreed to have her obtained ova fertilised using the sperm of 
WKHLQWHQGHGIDWKHU(PEU\RVQRWXVHGLQ0V&KRQQ¶VVXUURJDWHSUHJQDQF\ZHUHFU\RSUHVHUYHG
and stored by the IVF clinic. Sometime later an embryo containing her ovum and the sperm of 
the intended father was transferred to the uterus of the intended mother. Ms Chonn has stated 
that she was not informed that the embryo containing her ovum had been transferred to the 
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intended mother and that the use of the embryo occurred without her knowledge and written 
consent. Ms Chonn is genetically related to the child delivered by the intended mother. She has 
VWDWHGWKDW³she couldn't fathom someone else carrying her child.´The outcome has been 
especially stressful for her given her loss of contact with the intended parents and her genetic off-
spring.160   
 
This case exhibits a number of characteristics common to assisted reproduction. Roles can be 
variable and interchangeable.  Creation of human life and the intermixing of family and 
relational bonds are complex and potentially contested. Rules regarding the obtaining of consent 
are not always followed though in Canada, with the exception of when incident is reported by 
media, there exists no information on compliance to the Section 8 (Consent) Regulations.161 
Whether the Chonn incident is an outlier or indicative of a larger problem, we do not know as 
other instances have not come to public attention.  
 
I argue that the amendPHQWDWVFUHTXLULQJVFUHHQLQJDQGWHVWLQJRIWKHµREWDLQHG¶RYD
µGRQDWHG¶E\DZRPDQDQGXVHGLQKHUVXUURJDWHSUHJQDQF\PHDQVWKDWVKHcan be viewed as both 
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³The evil must be real and the apprehension of harm must be reasonable´ 
When the harm test established by the SCC in Ref re AHR to the situation of a traditional 
VXUURJDWHXVLQJKHURZQµREWDLQHG¶RYXPLQKHUVXUURJDWHSUHJQDQF\ is applied, WKLVSDSHU¶V
findings demonstrate that one encounters considerable difficulty in isolating specific health and 
safety risks capable of meriting criminal code sanctions being applied to the persons who would 
use an unscreened and untested ovum obtained from woman and used in her surrogate 
pregnancy. The paper can identify no health and safety risk posed by an unscreened and untested 
traditional surrogate¶VREWDLQHGRYXPto the woman herself, the IVF Clinic, its staff, or to stored 
human reproductive materials and embryos obtained from other patients 
  
A stronger argument can be found in the benefits to children born of a traditional surrogacy 
particularly if screening and testing could be applied to pin point the presence or absence of 
inheritable genetic diseases.  But as beneficent as genetic testing and the collection of donor 
health and medical history information may be, the 2012 amendment at 10(2)(c) will apply to an 
extremely small subset of traditional surrogate-born children. Yet without the commensurate 
requirement to maintain a donor registry, failure to screen and test becomes rather a hypothetical 
harm leading one to ask why genetic and health information is to be collected when traditional 
surrogate ovDDUHµREWDLQHG¶YLD,9)WUHDWPHQWbut not when traditional surrogacy occurs as a 
result of assisted insemination, which is by far the more common practice.   
 
It is important to recall the following summary of the remit of the AHRA as stated by the 
government when it announced its intentions to bring this section of the AHRA LQWRIRUFH³The 
Act protects individuals in Canada by setting out prohibited activities related to assisted human 
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reproduction that may pose significant human health and safety risks or that have been deemed 
WREHHWKLFDOO\XQDFFHSWDEOHRULQFRPSDWLEOHZLWK&DQDGLDQYDOXHV´162  The practice of 
commercial surrogacy is a prohibited activity as it been deemed to morally unacceptable and 
incompatible with Canadian values. An unscreened and tested ovum obtained from a woman and 
used in her surrogate pregnancy now falls into the category of prohibited activities on the basis 
of its risk to health and safety. Yet as this paper demonstrates, the µhealth and safety¶ test as laid 
out by the Supreme Court in Ref re AHRA cannot be sustained.  :KDWWKHQLVWKHµHYLO¶WKH
government sought to address when it amended the AHRA?  
 
I argue that traditional surrogacy is the µPRUDOevil¶ that the government wished to regulate under 
the guise of Dµhealth and safety HYLO¶when it imposed mandatory screening and testing of ova 
obtained from a donor and used in her surrogate pregnancy. Subsection 10(2)(c) functions as a 
backdoor means of marginalizing and discouraging the practice of traditional surrogacy enabled 
by assisted reproductive methods. Requiring that ova obtained from traditional surrogates be 
treated like other third-party ova discourages the practice, as not all clinics have the expertise or 
willingness to follow the procedures required to test and screen. This was the situation when the 
federal semen regulations were adopted in 1996 though some may argue that the testing and 
screen lite approach set for Designated Reproductive Donors in the 2017 CAN Standard will 
decrease the burden on IVF clinics.  
 
More troubling is the potential for confusion and mixing of roles of third-party donor, own use 
and traditional surrogacy that will be created. For example, clinics practices guidelines need to 
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be in place that traditional surrogates UHWDLQWKHDELOLW\WRH[HUFLVHFRQWURORYHUµREWDLQHG¶ova. 
The Section 8 (Consent) Regulations need to be significantly robust to ensure that the act of 
µREWDLQLQJ¶KHURYDZLOOnot infer with her right to determine who can use it for reproductive, 
training and research purposes. In part, a major source of potential confusion rests with the 
slipperiness and breadth RIWKH$+5$GHILQLWLRQRIµGRQRU.¶  Additional murkiness is created by 
the 2017 CAN/CSA Standard definition of µdonor¶ZKLFKZKHQDSSOLHGDWIDFHYDOXHZRXOG
logically imply that as the ova is being received by the person from which it originated, a 
traditional surrogate is not a Designated Reproductive Donor.  However, once the traditional 
VXUURJDWH¶Vova are reimagined to be a third-SDUW\µGRQDWHG¶RYD, then screening and testing 
protocols might then apply.  
 
Some may argue that while the traditional surrogate will be the recipient of an embryo comprised 
of her ovum and sperm donated by the intended father (or some other third-party), she is not the 
fertility patient as this term had been reserved by the IVF industry the intended parents as they 
are ones experiencing infertility.163 Again we have a difference of usage as the Ontario Fertility 
SURJUDPUHIHUVWRVXUURJDWHVLQUHFHLSWRI,9)DQGDVVLVWHGLQVHPLQDWLRQVHUYLFHVDVµSDWLHQWV¶ 
though as the Ms Chonn incident reveals this may not be the view shared by IVF clinics.  
  
The attempt by amendment to criminalise yet another aspect of surrogacy, in this case those who 
would facilitate the practice of IVF with traditional surrogates harkens back to the 1993 Baird 
                                                 
163
 See a discussion of who is a µIHUWLOLW\SDWLHQW¶LQWKHSDSHUE\3DPHOD0:KLWH³:K\ZHGRQ¶WNQRZZKDW
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Commission, ZKLFKVWDWHGWKDW³VXUURJDF\RIDQ\VRUWLVH[SORLWDWLYHDQGXQDFFHSWDEOH´164  By 
recommending prohibition of surrogacy, the Baird Commission sought ³to prevent psychological 
harm to the surrogate who may bond with her unborn FKLOGDQGWRVDYHZRPHQIURPWKHµHYLO¶RI
surrogacy´165  The 2004 Brown Commission Report, Building Families, written in response to 
proposed 2004 AHR legislation, continued to promote the view that: ³1RQ-commercial 
(altruistic) surrogacy arrangements can also be socially harmful for the resulting child and place 
WKHKHDOWKRIZRPHQDWULVN´166 Although the Commissioners agreed with the proposed of 
prohibition of surrogacy for commercial gain, they stated that ³surrogacy for non-commercial 
reasons should be discouraged but not criminalized.´167   
 
The amended 2012 AHRA at section 10(2)(c) seeks to do both. A health and safety argument is 
advanced to justify a OHJDOUHLPDJLQJRIWUDGLWLRQDOVXUURJDWH¶VERG\. Her ovum once obtained is 
transformed into a third-party gamete implying that its use will be determined by the intended 
parents.  
 
The AHRA uses criminal law powers to make it illegal for µobtained¶ traditional surrogate ova to 
be used by the surrogate in her pregnancy unless it is screened and tested. The implication of this 
amendment is that if the ovum is to be used in her surrogate pregnancy she will also need to 
relinquish control over its use for it becomes transformed through screening and testing into a 
third-party gamete created for the use of the intended parents. Her sphere of consent will now 
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reside with agreeing to a transfer of an embryo containing an ovum to which she retains genetic 
affinity but over which she can now exercise only limited control.  
 
The rationale for mandating criminal code powers requiring screening and testing of a traditional 
VXUURJDWH¶VRYXPLVEDVHGRQDQRn-existent health and safety concern.  The real ³evil´ in this 
arrangement is not one of health and safety but that of the use of criminal law powers to restrict 
autonomy in the practice of traditional surrogacy²a legally permissible practice when 
conducted altruistically.168 Once traditional surrogacy adopts reproductive technology practices 
enabling the removal of ovum from the body of the traditional surrogate, the frameworks of 
patient (intended parents), treatment options (surrogacy) and spare part provide (traditional 
surrogate as ova donor) take precedence. An analogy to this situation can found in a recent 
American anti-abortion legislation, Texas HB2, which was proposed as a patient health and 
safety protection measure, but which would have seriously transformed the ability of women to 




renewal is required.  Indeed had the section of the AHRA requiring parliamentary review of the 
Act (s.54) not been removed as part of the legislative housecleaning undertaken as part of the 
2012 AHRA amendments, one should have already been conducted. 
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I argue that the federal government cannot apply a health and safety justification to support 
criminal code penalties for failure to screen and test ovum obtained from a woman and used in 
her surrogate pregnancy for it fails to meet the test set out by the SCC.  More dangerous however 
are the underlying implications for consent and reproductive autonomy of a traditional surrogate 
undergoing IVF treatments.  Failure to tackle these matters is the µevil¶ that needs to be 
addressed.  
